VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human ...
Wataru Akahata, CEO of VLP Therapeutics Japan LLC, thinks he can help provide a solution to the challenge of securing COVID-19 vaccines for billions of people — the development of a second-generation ...
Icosavax has drawn up clinical trial plans for its new type of vaccine in a strategy to commence tests of multiple programs, including a Covid-19 candidate. But really, the startup is following a path ...
TOKYO -- VLP Therapeutics Japan has begun a clinical trial of a new coronavirus vaccine that would require a far smaller dosage than those of Pfizer and Moderna, and could dramatically shorten ...
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – The ongoing Phase 2 clinical trial of IVX-A12 ...
A clinical-grade recombinant virus-like particle (VLP) vaccine has been developed to prevent human parvovirus B19 (HPVB19) infection, which can have severe and potentially fatal complications in ...
Serum Institute of India (SII) has announced it has partnered with UK biotech company, Spybiotech, a spin-off of the University of Oxford, to develop a COVID-19 virus-like-particle (VLP)-based vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results